<DOC>
	<DOCNO>NCT02932605</DOCNO>
	<brief_summary>The main objective study compare microglia activation measure PET combination tracer [ 11C ] -R-PK11195 recent-onset schizophrenia patient randomise CBD randomise placebo .</brief_summary>
	<brief_title>Endocannabinoid Control Microglia Activation New Therapeutic Target Treatment Schizophrenia</brief_title>
	<detailed_description>Schizophrenia chronic severe mental disorder urgent need new effective treatment . A promising novel pharmacological target respect endocannabinoid system . In particular cannabinoid compound cannabidiol ( CBD ) display highly favourable profile development new antipsychotic agent . Increasing evidence indicate significant role neuroinflammation pathophysiology schizophrenia , especially activation resident macrophage brain : microglia . Interestingly , converge preclinical evidence suggest microglia activation control endocannabinoid system . However , manipulation endocannabinoid system affect microglia activation human establish , presumably related clinical improvement schizophrenia patient . In project , propose study endocannabinoid control microglia activation new therapeutic target treatment schizophrenia . Using placebo-controlled , randomised , double-blind design , investigate group 50 recent-onset schizophrenia patient four week daily CBD treatment , addition regular antipsychotic medication . First , examine CBD treatment attenuate microglia activation level peripheral inflammatory marker . In vivo microglia activation assess treatment use Positron Emission Tomography ( PET ) combination tracer [ 11C ] -R-PK11195 . Second , determine reduce microglia activation level inflammatory marker relate improvement symptomatology cognitive function . Third , ass microglia activation level inflammatory marker treatment predict clinical response CBD .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>A DSM diagnosis schizophrenia schizophreniform disorder define Comprehensive Assessment Symptoms History interview ( CASH ) ( Andreasen et al. , 1992 ) Age 18 40 Onset first psychosis longer five year ago Written inform consent subject Any clinically significant medical condition may influence result trial affect ability take part trial Routine laboratory screen value consider clinically relevant medical doctor Positive urine test drug abuse , except cannabis Treatment one antipsychotic agent unstable dose one type antipsychotic medication month prior study inclusion Use benzodiazepine , glucocorticosteroids nonsteroidal antiinflammatory drug ( NSAIDs ) within two week prior study inclusion Use comedication antipsychotic clinically relevant interaction cytochrome P450 ( CYP ) 2C19 CYP3A class liver enzymes within two week prior study inclusion ( CBD may inhibitor class liver enzymes ) Intake investigational drug within one month prior study inclusion Current aggression dangerous behaviour ( PANSS G14 score 5 ) Current suicidality / selfharm ( PANSS G6 score 7 ) A history alcohol substance dependence ( except nicotine ) within six month prior study inclusion measure CASH Any current previous neurological disorder , include epilepsy History head injury result unconsciousness last least 1 hour IQ &lt; 70 , measure Dutch version National Adult Reading Test ( DART ) Breastfeeding , pregnancy attempt conceive Significant radiation exposure inclusion study take total dose &gt; 10mSv within precede 12 month . MRI contraindication , e.g . claustrophobia metal object around body</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cannabidiol</keyword>
	<keyword>Positron Emission Tomography ( PET )</keyword>
	<keyword>Microglia</keyword>
</DOC>